RenalytixAI
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
5-7 Cranwood St, London, Greater London,...Phone Number
(646) 397-3970Website
www.renalytix.comRevenue
<$5 MillionStock Symbol
RNLXIndustry
About RenalytixAI
RenalytixAI Org Chart
Is RenalytixAI your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if RenalytixAI had a recent Job posting/layoffs
Product Launch: Get notified when RenalytixAI launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if RenalytixAI has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on RenalytixAI recently announced quarterly report
RenalytixAI, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once RenalytixAI has new funding data
Check out if RenalytixAI is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at RenalytixAI
Recommended Actions
Find VP level buyers at RenalytixAI
Find 2 more new buyers
Compare Similar Companies to RenalytixAI
Compare insights from companies similar to RenalytixAI, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
RenalytixAI is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
RenalytixAI is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about RenalytixAI.
RenalytixAI financials insights
Gather financial insights about RenalytixAI, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Other Financing Round
$29M
Stock Offering
$74M
Share Placement
$30M
RenalytixAI Tech Stack
A closer look at the technologies used by RenalytixAI
Most Recent Scoops
RenalytixAI News & Media
Renalytix shares fall 25% as revenues miss expectations
Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) shares dropped 25% to 4.25p after the company posted first-half revenues of $1.6 million and flagged slower-than-expected progress in rolling out its kidney disease diagnostic test. The company, which develops the FDA-approved and...Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
New results and three presentations at ASN Kidney Week underscore kidneyintelX.dkd as a precision-medicine standard for CKD NEW YORK, Nov. 18, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision-medicine diagnostics company for kidney health and developer of...Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), today announced an...MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities
New partnership expands access to prognostic testing for people with diabetic kidney disease, helping improve lives and reduce health disparities. NEW YORK, July 21, 2025 /PRNewswire/ -- Renalytix Plc, a precision medicine company focused on chronic disease, and MVP Health Care, a...
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RenalytixAI
Renalytix is dedicated to eradicating kidney disease through its innovative KidneyIntelX technology, which helps clinical teams assess patient risk for the progression of diabetic kidney disease at early stages. By identifying patient risk early, clinicians can allocate resources and treatments effectively, ultimately improving health outcomes for... Read More